Avantor (NYSE:AVTR) Price target cut to $44.00 by Cowen analysts


Forward (NYSE: AVTRGet a rating) saw its price target lowered by investment analysts Cowen from $50.00 to $44.00 in a research note released on Tuesday, Target Stock Advisor reports. Cowen’s price target indicates a potential upside of 40.71% from the stock’s previous close.

AVTR has been the subject of a number of other reports. Cowen cut his price target on Avantor shares from $50.00 to $44.00 in a research note on Tuesday. Citigroup cut Avantor shares from a “buy” rating to a “neutral” rating and lowered its price target for the stock from $48.00 to $38.00 in a Monday research report 4 april. Zacks Investment Research upgraded Avantor from a “hold” rating to a “sell” rating in a research report on Monday. Barclays raised its price target on Avantor from $41.00 to $44.00 and gave the company an “overweight” rating in a Monday, February 7 research report. Finally, Morgan Stanley cut its price target on Avantor from $46.00 to $43.00 and set an “overweight” rating for the company in a Monday, Feb. 7 research report. One research analyst rated the stock with a sell rating, one gave the company a hold rating and fourteen gave the company a buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $43.59.

Shares of NYSE: AVTR traded down $0.26 during Tuesday trading hours, hitting $31.27. 32,624 shares of the company have traded, compared to its average volume of 4,653,831. The company has a leverage ratio of 2.19, a quick ratio of 1.11 and a current ratio of 1.71. The company’s fifty-day simple moving average is $33.86 and its two-hundred-day simple moving average is $37.06. Avantor has a 52-week low of $29.58 and a 52-week high of $44.37. The company has a market capitalization of $19.07 billion, a price-to-earnings ratio of 36.40, a growth price-to-earnings ratio of 0.68 and a beta of 1.62.

Forward (NYSE: AVTRGet a rating) last released its quarterly results on Thursday, February 3. The company reported earnings per share (EPS) of $0.36 for the quarter, beating Thomson Reuters consensus estimate of $0.33 by $0.03. The company posted revenue of $1.91 billion for the quarter, compared to analysts’ estimates of $1.90 billion. Avantor had a net margin of 7.53% and a return on equity of 35.81%. In the same quarter a year earlier, the company posted earnings of $0.29 per share. On average, analysts expect Avantor to post 1.5 EPS for the current fiscal year.

In other news, EVP Gerard Brophy sold 3,059 shares of the company in a transaction that took place on Wednesday, February 23. The stock was sold at an average price of $33.79, for a total transaction of $103,363.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via the SEC website. Insiders hold 1.60% of the shares of the company.

Several institutional investors and hedge funds have recently increased or reduced their stake in the company. Procyon Advisors LLC acquired a new position in shares of Avantor in the first quarter worth $215,000. AE Wealth Management LLC increased its equity stake in Avantor by 5.3% in Q1. AE Wealth Management LLC now owns 34,669 shares of the company valued at $1,173,000 after purchasing an additional 1,744 shares last quarter. IFM Investors Pty Ltd increased its stake in Avantor shares by 18.7% during the first quarter. IFM Investors Pty Ltd now owns 81,324 shares in the company worth $2,750,000 after acquiring an additional 12,830 shares during the period. Paradiem LLC increased its position in Avantor shares by 3.3% during the first quarter. Paradiem LLC now owns 82,684 shares of the company valued at $2,651,000 after acquiring an additional 2,650 shares last quarter. Finally, DeDora Capital Inc. purchased a new stake in Avantor in the first quarter worth approximately $1,124,000. Institutional investors and hedge funds own 92.46% of the company’s shares.

About Avantor (Get a rating)

Avantor, Inc provides products and services to biopharmaceutical, healthcare, education and government, advanced technology and applied materials customers in the Americas, Europe, Asia, the Middle East and Africa. The Company offers materials and consumables, such as purity chemicals and reagents, laboratory products and supplies, formulated silicone materials, custom excipients, custom single-use assemblies, resins and columns. chromatography kits, analytical sample preparation kits, education and microbiology products, clinical trial kits, peristaltic pumps and fluid handling tips.

See also

Stock Target Advisor logo

Analyst Recommendations for Avantor (NYSE: AVTR)



Get news and reviews for Avantor Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Avantor and related companies with MarketBeat.com’s free daily email newsletter.